ALK and non-small cell lung carcinoma: For example, a study by Zhu et al. treated untreated clinical stage II-III and wild-type EGFR/ALK NSCLC patients with neoadjuvant toripalimab (a PD-1 inhibitor) combined with carboplatin (Zhu et al., 2022).